Next generation antidepressants : moving beyond monoamines to discover novel treatment strategies for mood disorders

Author(s)

Bibliographic Information

Next generation antidepressants : moving beyond monoamines to discover novel treatment strategies for mood disorders

edited by Chad E. Beyer and Stephen M. Stahl

(Cambridge medicine)

Cambridge University Press, 2010

  • : hardback

Available at  / 1 libraries

Search this Book/Journal

Note

Includes bibliographical references and index

Contents of Works

  • Current depression landscape : a state of the field today / Laurence Mignon and Stephen M. Stahl
  • Novel therapeutic targets for treating affective disorders / Eliyahu Dremencov and Thomas I. F. H. Cremers
  • Developing novel animal models of depression / Lotte de Groote, Malgorzata Filip, and Andrew C. McCreary
  • Translational research in mood disorders : using imaging technologies in biomarker research / Jul Lea Shamy ... [et al.]
  • Defining depression endophenotypes / Lisa H. Berghorst and Diego A. Pizzagalli
  • Genetic and genomic studies of major depressive disorder / Roy H. Perlis
  • Medicinal chemistry challenges in the design of next generation antidepressants / David P. Rotella
  • Application of pharmacogenomics and personalized medicine for the care of depression / Keh-Ming Lin, Chun-Yu Chen, and Yu-Jui Yvonne Wan

Description and Table of Contents

Description

The World Health Organization defines depression as a primary contributor to the global burden of disease and predicts it will become the second leading cause of death by 2020. The need to develop effective therapies has never been so pressing. Current antidepressant drugs have several limitations. This 2010 book looks at the future of mood-disorder research, covering the identification of new therapeutic targets, establishing new preclinical models, new medicinal chemistry opportunities, and fostering greater understanding of genetic influences. These strategies are likely to help build a better picture of the disease process, and lead to new opportunities for patient stratification and treatment. The ultimate goal for this strand of research is to develop more personalized and effective treatments for this chronic and debilitating condition. This is essential reading for all those involved in psychopharmacologic drug development, and mental health clinicians seeking a preview of discoveries soon to influence their practice.

Table of Contents

  • Preface Chad E. Beyer
  • 1. Current depression landscape: a state of the field today Laurence Mignon and Stephen M. Stahl
  • 2. Novel therapeutic targets for treating affective disorders Eliyahu Dremencov and Thomas Cremers
  • 3. Developing novel animal models of depression Lotte de Groote, Malgorzata Filip and Andrew C. McCreary
  • 4. Translational research in mood disorders: using imaging technologies in biomarker research Jul Lea Shamy, Adam M. Brickman, Chris D. Griesemer, Anna Parachikova and Mark Day
  • 5. Defining depression endophenotypes Lisa H. Berghorst and Diego A. Pizzagalli
  • 6. Genetic and genomic studies of major depressive disorder Roy H. Perlis
  • 7. Medicinal chemistry challenges in the design of next generation antidepressants David P. Rotella
  • 8. Application of pharmacogenomics and personalized medicine for the care of depression Keh-Ming Lin, Chun-Yu Chen and Yu-Jui Yvonne Wan
  • Index.

by "Nielsen BookData"

Related Books: 1-1 of 1

Details

  • NCID
    BB08570455
  • ISBN
    • 9780521760584
  • Country Code
    uk
  • Title Language Code
    eng
  • Text Language Code
    eng
  • Place of Publication
    Cambridge ; Tokyo
  • Pages/Volumes
    xi, 137 p.
  • Size
    24 cm
  • Classification
  • Subject Headings
  • Parent Bibliography ID
Page Top